|
Hematology
|
| Protocol # |
Principal Investigator |
Title |
| UCI 04-04 |
Ong |
A Phase I Study of CCI-779 in Combination with Imatinib Mesylate in Chronic Myelogenous Leukemia
(ON HOLD) |
| UCI 05-53 |
Sender |
A Randomized, Open-Label, Multicenter Study of VELCADE with Rituximab or Rituximab Alone in Subjects with Relapsed or Refractory, Rituximab naive or Sensitive Follicular B-cell Non-Hodgkin's Lymphoma (Phase 3) |
| UCI 04-04 |
Ong |
A Phase I Study of CCI-779 in Combination with Imatinib Mesylate in Chronic Myelogenous Leukemia |
| UCI 01-59 |
Ong |
Development of a Diagnostic Assay for Kinase Activity in Malignant Cells |
| UCI 05-06 |
Sender |
CLI-037: A Phase III Randomized Study of CLORETAZINE (VNP40101M) and Cytosine Arabinoside (AraC) in patients with acute Myeloid Leukemia in First Relapse
(TEMPORARILY ON HOLD) |
| UCI 05-53 |
Sender |
A Randomized, Open-Label, Multicenter Study of VELCADE with Rituximab or Rituximab Alone in Subjects with Relapsed or Refractory, Rituximab naive or Sensitive Follicular B-Cell Non-Hodgkin's Lymphoma (Phase 3) |
| SWOG S0313 |
Sender |
Evaluation of CHOP plus Involved in Field Radiotherapy followed by Yttium-90 Ibritumomab Tiuxetan For Stages I, IE, and Non- Bulky Stages II and IIE, CD20 Positive, High-Risk Localized, Aggressive Histologies of Non Hodgkin's Lymphoma, Phase II
(TEMPORARILY ON HOLD) |
| SWOG S0016-R |
Sender |
A Phase III Trial of CHOP + Rituximab vs. CHOP + Iodine-131-Labeled Monoclonal Anti-B1 Antibody (Tositumomab) for Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphomas |
| SWOG S0301 |
Sender |
A Phase II Study of Induction with Daunorubicin, Cytarabine, and Cyclosporine all by Continuous IV Infusion for Previously Untreated Non-M3 Acute Myeloid Leukemia |
| SWOG S0515 |
Sender |
Phase II Trial of Standard Dose Cyclophosphamide,
Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab Plus Bevacizumab for Advanced Stage Diffuse Large B-Cell NHL |
| SWOG S9910 |
Sender |
Leukemia Centralized Reference laboratories and Tissue Repositories – Consent to Perform Cellular and Molecular Studies in Leukemia Subjects |
| SWOG-9007 |
Holcombe |
Cytogenic Studies in Leukemia Patients (Formerly SWOG
S9007) |
| SWOG S0530 |
Ou |
A Phase II Trial of Cytarabine and Clofarabine in
Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) |
For additional information on open UCI clinical trials please call toll-free 1-877-UC-STUDY or email ucstudy@uci.edu.
